| Year |
Citation |
Score |
| 2023 |
Wang J, Chen T, Ruszaj DM, Mager DE, Straubinger RM. Integrated PK/PD modeling relates Smoothened inhibitor biomarkers to the heterogeneous intratumor disposition of cetuximab in pancreatic cancer tumor models. Journal of Pharmaceutical Sciences. PMID 37844759 DOI: 10.1016/j.xphs.2023.10.019 |
0.566 |
|
| 2023 |
Mager DE, Straubinger RM. Contributions of William Jusko to Development of Pharmacokinetic and Pharmacodynamic Models and Methods. Journal of Pharmaceutical Sciences. PMID 37778439 DOI: 10.1016/j.xphs.2023.09.019 |
0.573 |
|
| 2022 |
Allen-Coyle TJ, Niu J, Welsch E, Conlon NT, Garner W, Clynes M, O'Sullivan F, Straubinger RM, Mager DE, Roche S. FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. The Aaps Journal. 24: 108. PMID 36229752 DOI: 10.1208/s12248-022-00752-8 |
0.568 |
|
| 2021 |
Heineman T, Baumgart M, Nanavati C, Gabrail N, Van Wart SA, Mager DE, Maneval DC, Fathallah AM, Sekulovich RE. Safety and Pharmacokinetics of Docetaxel in Combination with Pegvorhyaluronidase Alfa (PVHA; PEGPH20) in Patients with Non-Small-Cell Lung Cancer. Clinical and Translational Science. PMID 33982408 DOI: 10.1111/cts.13041 |
0.651 |
|
| 2021 |
Van Wart S, Mager DE, Bednasz CJ, Huizing M, Carrillo N. Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy. Drugs in R&D. PMID 33893973 DOI: 10.1007/s40268-021-00343-6 |
0.624 |
|
| 2021 |
Lin Q, Qian Z, Jusko WJ, Mager DE, Ma WW, Straubinger RM. Synergistic pharmacodynamic effects of gemcitabine and fibroblast growth factor receptor inhibitors on pancreatic cancer cell cycle kinetics and proliferation. The Journal of Pharmacology and Experimental Therapeutics. PMID 33753538 DOI: 10.1124/jpet.120.000412 |
0.664 |
|
| 2020 |
Niu J, Wang X, Qu J, Mager DE, Straubinger RM. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells. Bmc Cancer. 20: 1024. PMID 33097020 DOI: 10.1186/s12885-020-07398-9 |
0.537 |
|
| 2020 |
Greene MK, Chen T, Robinson E, Straubinger NL, Minx C, Chan DKW, Wang J, Burrows JF, Van Schaeybroeck S, Baker JR, Caddick S, Longley DB, Mager DE, Straubinger RM, Chudasama V, et al. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer. PMID 32913288 DOI: 10.1038/S41416-020-01046-6 |
0.589 |
|
| 2020 |
Zhang L, Mager DE. Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients. Journal of Pharmacokinetics and Pharmacodynamics. PMID 31939004 DOI: 10.1007/S10928-019-09670-3 |
0.433 |
|
| 2020 |
Chen T, Zheng Y, Roskos L, Mager DE. Predicting overall survival (OS) and overall response (OR) following durvalumab treatment in patients with multiple cancer types using a hybrid modeling strategy. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15161 |
0.31 |
|
| 2019 |
Niu J, Straubinger RM, Mager DE. Pharmacodynamic Drug-Drug Interactions. Clinical Pharmacology and Therapeutics. PMID 30912119 DOI: 10.1002/Cpt.1434 |
0.634 |
|
| 2019 |
Morcos PN, Boehnke A, Valente N, Mager DE. Rituximab dosing in hematological malignancies: an old question, revisited. Cancer Chemotherapy and Pharmacology. PMID 30899984 DOI: 10.1007/S00280-019-03818-1 |
0.301 |
|
| 2019 |
Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrobial Agents and Chemotherapy. PMID 30642925 DOI: 10.1128/Aac.01638-18 |
0.336 |
|
| 2019 |
Bloomingdale P, Mager DE. Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy. Pharmaceutical Research. 36: 35. PMID 30617559 DOI: 10.1007/S11095-018-2562-7 |
0.352 |
|
| 2019 |
Niu J, Wang X, Shen S, Qu J, Mager D, Straubinger RM. Abstract 3890: Pharmacodynamic and proteomic analysis of combined gemcitabine/nab-paclitaxel in patient-derived pancreatic cancer xenograft models Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3890 |
0.586 |
|
| 2018 |
Zhang L, Mager DE. Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients. Journal of Pharmaceutical Sciences. PMID 30472266 DOI: 10.1016/J.Xphs.2018.11.024 |
0.314 |
|
| 2018 |
Campagne O, Mager DE, Tornatore KM. Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? Journal of Clinical Pharmacology. PMID 30371942 DOI: 10.1002/Jcph.1325 |
0.376 |
|
| 2018 |
Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients. Journal of Clinical Pharmacology. PMID 29775201 DOI: 10.1002/Jcph.1118 |
0.331 |
|
| 2018 |
Ramakrishnan V, Mager DE. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells. The Journal of Pharmacology and Experimental Therapeutics. PMID 29632237 DOI: 10.1124/Jpet.118.247924 |
0.328 |
|
| 2018 |
Bloomingdale P, Nguyen VA, Niu J, Mager DE. Boolean network modeling in systems pharmacology. Journal of Pharmacokinetics and Pharmacodynamics. PMID 29307099 DOI: 10.1007/S10928-017-9567-4 |
0.365 |
|
| 2018 |
Wang Q, Cook SF, Van Wart SA, Mager DE, Faderl S. Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy Blood. 132: 4037-4037. DOI: 10.1182/Blood-2018-99-111918 |
0.348 |
|
| 2017 |
Bloomingdale P, Housand C, Apgar JF, Millard BL, Mager DE, Burke JM, Shah DK. Quantitative systems toxicology. Current Opinion in Toxicology. 4: 79-87. PMID 29308440 DOI: 10.1016/J.Cotox.2017.07.003 |
0.416 |
|
| 2017 |
Ait-Oudhia S, Zhang W, Mager DE. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. The Aaps Journal. PMID 28646408 DOI: 10.1208/S12248-017-0113-5 |
0.413 |
|
| 2017 |
Cirincione B, Sager PT, Mager DE. Influence of Meals and Glycemic Changes on QT Interval Dynamics. Journal of Clinical Pharmacology. PMID 28543601 DOI: 10.1002/Jcph.933 |
0.337 |
|
| 2017 |
Cirincione B, LaCreta F, Sager P, Mager DE. Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion. Journal of Clinical Pharmacology. PMID 28543393 DOI: 10.1002/Jcph.882 |
0.34 |
|
| 2017 |
Nanavati C, Mager DE. Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells. Pharmaceutical Research. PMID 28101809 DOI: 10.1007/S11095-017-2095-5 |
0.313 |
|
| 2016 |
Cirincione B, Edwards J, Mager DE. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. The Aaps Journal. PMID 27896683 DOI: 10.1208/S12248-016-9975-1 |
0.381 |
|
| 2016 |
Ait-Oudhia S, Mager DE. Array of translational systems pharmacodynamic models of anti-cancer drugs. Journal of Pharmacokinetics and Pharmacodynamics. PMID 27771815 DOI: 10.1007/S10928-016-9497-6 |
0.435 |
|
| 2016 |
Jiang XL, Shen HW, Mager DE, Schmidt S, Yu AM. Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. Acta Pharmaceutica Sinica. B. 6: 492-503. PMID 27709018 DOI: 10.1016/J.Apsb.2016.07.007 |
0.416 |
|
| 2016 |
Ait-Oudhia S, Ovacik MA, Mager DE. Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. Mabs. 0. PMID 27661132 DOI: 10.1080/19420862.2016.1238995 |
0.431 |
|
| 2016 |
Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-Factor VIII antibodies in Hemophilia A mice. Biopharmaceutics & Drug Disposition. PMID 27418232 DOI: 10.1002/Bdd.2023 |
0.345 |
|
| 2016 |
Nanavati C, Mager DE. Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts. Journal of Pharmaceutical Sciences. 105: 1561-6. PMID 27019967 DOI: 10.1016/J.Xphs.2016.01.026 |
0.405 |
|
| 2015 |
Ramakrishnan V, Yang QJ, Quach HP, Cao Y, Chow EC, Mager DE, Pang KS. Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1α,25-Dihydroxyvitamin D3 in Mice: Comparison of Minimal and Full PBPK-PD Models. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26586377 DOI: 10.1124/Dmd.115.067033 |
0.361 |
|
| 2015 |
Zhang L, Mager DE. Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. Journal of Pharmacokinetics and Pharmacodynamics. 42: 541-52. PMID 26391023 DOI: 10.1007/S10928-015-9445-X |
0.43 |
|
| 2015 |
Jin JY, Mager DE. The American Conference on Pharmacometrics 2015 (ACoP6). Journal of Pharmacokinetics and Pharmacodynamics. 42: 1-2. PMID 26370673 DOI: 10.1007/S10928-015-9431-3 |
0.398 |
|
| 2015 |
Chudasama VL, Ovacik MA, Abernethy DR, Mager DE. Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells. The Journal of Pharmacology and Experimental Therapeutics. 354: 448-58. PMID 26163548 DOI: 10.1124/Jpet.115.224766 |
0.776 |
|
| 2015 |
Chudasama VL, Zutshi A, Singh P, Abraham AK, Mager DE, Harrold JM. Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. Journal of Pharmacokinetics and Pharmacodynamics. 42: 1-18. PMID 25559227 DOI: 10.1007/S10928-014-9401-1 |
0.752 |
|
| 2015 |
Fathallah AM, Turner MR, Mager DE, Balu-Iyer SV. Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharmaceutics & Drug Disposition. 36: 115-25. PMID 25377184 DOI: 10.1002/Bdd.1925 |
0.361 |
|
| 2015 |
McCune JS, Vicini P, Salinger DH, O'Donnell PV, Sandmaier BM, Anasetti C, Mager DE. Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemotherapy and Pharmacology. 75: 67-75. PMID 25374408 DOI: 10.1007/S00280-014-2618-2 |
0.345 |
|
| 2015 |
Kulshrestha M, Sola-Visner M, Widness JA, Veng-Pedersen P, Mager DE. Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates. American Journal of Physiology. Heart and Circulatory Physiology. 308: H68-73. PMID 25362135 DOI: 10.1152/Ajpheart.00528.2013 |
0.33 |
|
| 2015 |
Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. Journal of Pharmaceutical Sciences. 104: 388-95. PMID 24700333 DOI: 10.1002/Jps.23963 |
0.312 |
|
| 2014 |
Kagan L, Zhao J, Mager DE. Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharmaceutical Research. 31: 3265-73. PMID 24852895 DOI: 10.1007/S11095-014-1416-1 |
0.317 |
|
| 2014 |
Li H, Mager DE, Sandmaier BM, Storer BE, Boeckh MJ, Bemer MJ, Phillips BR, Risler LJ, McCune JS. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1121-9. PMID 24727337 DOI: 10.1016/J.Bbmt.2014.03.032 |
0.381 |
|
| 2014 |
Ait-Oudhia S, Mager DE, Straubinger RM. Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics. 6: 137-74. PMID 24647104 DOI: 10.3390/Pharmaceutics6010137 |
0.635 |
|
| 2014 |
Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV. Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharmaceutics & Drug Disposition. 35: 154-63. PMID 24259187 DOI: 10.1002/Bdd.1880 |
0.343 |
|
| 2014 |
Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of furosemide pharmacokinetics. Biopharmaceutics & Drug Disposition. 35: 119-33. PMID 24151207 DOI: 10.1002/Bdd.1874 |
0.69 |
|
| 2014 |
Kagan L, Gershkovich P, Wasan KM, Mager DE. Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Pharmaceutical Research. 31: 35-45. PMID 23793994 DOI: 10.1007/S11095-013-1127-Z |
0.35 |
|
| 2013 |
Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. Biopharmaceutics & Drug Disposition. 34: 527-39. PMID 24123104 DOI: 10.1002/Bdd.1863 |
0.69 |
|
| 2013 |
Harrold JM, Ramanathan M, Mager DE. Network-based approaches in drug discovery and early development. Clinical Pharmacology and Therapeutics. 94: 651-8. PMID 24025802 DOI: 10.1038/Clpt.2013.176 |
0.351 |
|
| 2013 |
Chen T, Kagan L, Mager DE. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. Journal of Pharmaceutical Sciences. 102: 3844-51. PMID 23897494 DOI: 10.1002/Jps.23682 |
0.343 |
|
| 2013 |
Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Biopharmaceutics & Drug Disposition. 34: 336-47. PMID 23794414 DOI: 10.1002/Bdd.1849 |
0.667 |
|
| 2013 |
Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV. Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. Journal of Pharmaceutical Sciences. 102: 2380-94. PMID 23620343 DOI: 10.1002/Jps.23566 |
0.309 |
|
| 2013 |
Jiang XL, Shen HW, Mager DE, Yu AM. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 975-86. PMID 23393220 DOI: 10.1124/Dmd.112.050724 |
0.365 |
|
| 2013 |
Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. Journal of Clinical Pharmacology. 53: 393-402. PMID 23382105 DOI: 10.1002/Jcph.14 |
0.362 |
|
| 2013 |
Chen T, Mager DE, Kagan L. Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharmaceutical Research. 30: 751-60. PMID 23229855 DOI: 10.1007/S11095-012-0917-Z |
0.354 |
|
| 2013 |
Kagan L, Mager DE. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 248-55. PMID 23129212 DOI: 10.1124/Dmd.112.048496 |
0.341 |
|
| 2013 |
Ait-Oudhia S, Straubinger RM, Mager DE. Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. The Journal of Pharmacology and Experimental Therapeutics. 344: 103-12. PMID 23115220 DOI: 10.1124/Jpet.112.199109 |
0.638 |
|
| 2012 |
Felmlee MA, Morris ME, Mager DE. Mechanism-based pharmacodynamic modeling. Methods in Molecular Biology (Clifton, N.J.). 929: 583-600. PMID 23007443 DOI: 10.1007/978-1-62703-050-2_21 |
0.432 |
|
| 2012 |
Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, Frey N, Mager DE. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clinical Pharmacology and Therapeutics. 92: 520-7. PMID 22968044 DOI: 10.1038/Clpt.2012.153 |
0.763 |
|
| 2012 |
Roy Chaudhuri T, Arnold RD, Yang J, Turowski SG, Qu Y, Spernyak JA, Mazurchuk R, Mager DE, Straubinger RM. Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation. Pharmaceutical Research. 29: 3312-24. PMID 22798260 DOI: 10.1007/S11095-012-0823-4 |
0.543 |
|
| 2012 |
Mager DE, Mody V, Xu C, Forrest A, Lesniak WG, Nigavekar SS, Kariapper MT, Minc L, Khan MK, Balogh LP. Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition. Pharmaceutical Research. 29: 2534-42. PMID 22688900 DOI: 10.1007/S11095-012-0784-7 |
0.432 |
|
| 2012 |
Ait-Oudhia S, Straubinger RM, Mager DE. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharmaceutical Research. 29: 2833-44. PMID 22588463 DOI: 10.1007/S11095-012-0775-8 |
0.613 |
|
| 2012 |
Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Science Translational Medicine. 4: 126ps7. PMID 22440734 DOI: 10.1126/Scitranslmed.3003563 |
0.395 |
|
| 2012 |
Harrold JM, Straubinger RM, Mager DE. Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Research. 72: 1632-41. PMID 22350416 DOI: 10.1158/0008-5472.Can-11-2432 |
0.628 |
|
| 2012 |
Li H, Mager DE, Bemer MJ, Salinger DH, Vicini P, Sandmaier BM, Nash R, McCune JS. A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. Journal of Clinical Pharmacology. 52: 1654-64. PMID 22174435 DOI: 10.1177/0091270011429567 |
0.329 |
|
| 2012 |
Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharmaceutical Research. 29: 490-9. PMID 21887597 DOI: 10.1007/S11095-011-0578-3 |
0.334 |
|
| 2012 |
Kastrissios H, Walker JR, Carrothers TJ, Kshirsagar S, Khariton T, Habtemariam B, Mager DE, Rohatagi S. Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites. Journal of Clinical Pharmacology. 52: 404-15. PMID 21422240 DOI: 10.1177/0091270010396373 |
0.378 |
|
| 2012 |
Chudasama VL, Mager DE. Abstract 4944: Crosstalk between NFκB and STAT3 in human multiple myeloma cells (U266) Cancer Research. 72: 4944-4944. DOI: 10.1158/1538-7445.Am2012-4944 |
0.74 |
|
| 2012 |
Ait-Oudhia S, Straubinger RM, Mager DE. Abstract 3980: Computational analysis of paclitaxel-induced tumor priming that leads to enhanced deposition and efficacy nanoparticulate doxorubicin Cancer Research. 72: 3980-3980. DOI: 10.1158/1538-7445.Am2012-3980 |
0.552 |
|
| 2011 |
Marathe DD, Marathe A, Mager DE. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharmaceutics & Drug Disposition. 32: 471-81. PMID 21953540 DOI: 10.1002/Bdd.770 |
0.317 |
|
| 2011 |
Abraham AK, Maurer TS, Kalgutkar AS, Gao X, Li M, Healy DR, Petersen DN, Griffith DA, Mager DE. Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor. The Aaps Journal. 13: 265-73. PMID 21437757 DOI: 10.1208/S12248-011-9266-9 |
0.705 |
|
| 2011 |
Kagan L, Gershkovich P, Wasan KM, Mager DE. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. The Aaps Journal. 13: 255-64. PMID 21431453 DOI: 10.1208/S12248-011-9267-8 |
0.411 |
|
| 2011 |
Marathe A, Van Wart S, Mager DE. Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics. 38: 223-35. PMID 21165681 DOI: 10.1007/S10928-010-9190-0 |
0.698 |
|
| 2011 |
Kosloski MP, Peng A, Varma PR, Fathallah AM, Miclea RD, Mager DE, Balu-iyer SV. Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates. Drug Delivery. 18: 246-54. PMID 21114461 DOI: 10.3109/10717544.2010.536269 |
0.31 |
|
| 2011 |
Xu C, Mager DE. Quantitative structure-pharmacokinetic relationships. Expert Opinion On Drug Metabolism & Toxicology. 7: 63-77. PMID 21105864 DOI: 10.1517/17425255.2011.537257 |
0.521 |
|
| 2010 |
D'Argenio DZ, Mager DE. Bridging pharmacology and pathophysiology via systems modeling. Journal of Clinical Pharmacology. 50: 56S-57S. PMID 20881218 DOI: 10.1177/0091270010377505 |
0.308 |
|
| 2010 |
Kagan L, Dreifinger T, Mager DE, Hoffman A. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 1560-6. PMID 20538723 DOI: 10.1124/Dmd.110.033019 |
0.346 |
|
| 2010 |
Houzé P, Mager DE, Risède P, Baud FJ. Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicity. Toxicological Sciences : An Official Journal of the Society of Toxicology. 116: 660-72. PMID 20498006 DOI: 10.1093/Toxsci/Kfq152 |
0.403 |
|
| 2010 |
Abraham AK, Kagan L, Kumar S, Mager DE. Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. The Journal of Pharmacology and Experimental Therapeutics. 334: 327-32. PMID 20406858 DOI: 10.1124/Jpet.110.167650 |
0.682 |
|
| 2010 |
Kagan L, Abraham AK, Harrold JM, Mager DE. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharmaceutical Research. 27: 920-32. PMID 20232116 DOI: 10.1007/S11095-010-0098-6 |
0.683 |
|
| 2010 |
Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics. 37: 25-47. PMID 20012173 DOI: 10.1007/S10928-009-9142-8 |
0.337 |
|
| 2010 |
Yang J, Mager DE, Straubinger RM. Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. The Aaps Journal. 12: 1-10. PMID 19902363 DOI: 10.1208/S12248-009-9155-7 |
0.641 |
|
| 2010 |
Zhou R, Mazurchuk RV, Tamburlin JH, Harrold JM, Mager DE, Straubinger RM. Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. The Journal of Pharmacology and Experimental Therapeutics. 332: 479-88. PMID 19861574 DOI: 10.1124/Jpet.109.160044 |
0.603 |
|
| 2010 |
Xu C, Barchet TM, Mager DE. Quantitative structure–property relationships of camptothecins in humans. Cancer Chemotherapy and Pharmacology. 65: 325-33. PMID 19488755 DOI: 10.1007/S00280-009-1037-2 |
0.493 |
|
| 2009 |
Walker JR, Brown K, Rohatagi S, Bathala MS, Xu C, Wickremasingha PK, Salazar DE, Mager DE. Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). Journal of Clinical Pharmacology. 49: 1185-95. PMID 19783712 DOI: 10.1177/0091270009340783 |
0.494 |
|
| 2009 |
Marathe A, Krzyzanski W, Mager DE. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. Journal of Pharmacokinetics and Pharmacodynamics. 36: 199-219. PMID 19434483 DOI: 10.1007/S10928-009-9118-8 |
0.425 |
|
| 2009 |
Abraham AK, Ramanathan M, Weinstock-Guttman B, Mager DE. Mechanisms of interferon-beta effects on bone homeostasis. Biochemical Pharmacology. 77: 1757-62. PMID 19428330 DOI: 10.1016/J.Bcp.2009.01.007 |
0.627 |
|
| 2009 |
Abraham AK, Mager DE, Gao X, Li M, Healy DR, Maurer TS. Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans. The Journal of Pharmacology and Experimental Therapeutics. 330: 169-78. PMID 19386792 DOI: 10.1124/Jpet.109.152033 |
0.666 |
|
| 2009 |
Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metabolism and Pharmacokinetics. 24: 16-24. PMID 19252333 DOI: 10.2133/Dmpk.24.16 |
0.656 |
|
| 2008 |
Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. The Journal of Pharmacology and Experimental Therapeutics. 326: 555-62. PMID 18460643 DOI: 10.1124/Jpet.108.137703 |
0.431 |
|
| 2008 |
Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clinical Pharmacology and Therapeutics. 83: 909-12. PMID 18388873 DOI: 10.1038/Clpt.2008.52 |
0.555 |
|
| 2008 |
Hong Y, Rohatagi S, Habtemariam B, Walker JR, Schwartz SL, Mager DE. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. Journal of Clinical Pharmacology. 48: 696-707. PMID 18372428 DOI: 10.1177/0091270008316884 |
0.374 |
|
| 2008 |
Hong Y, Dingemanse J, Mager DE. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. Clinical Pharmacology and Therapeutics. 84: 136-43. PMID 18288088 DOI: 10.1038/Sj.Clpt.6100495 |
0.367 |
|
| 2008 |
Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clinical Pharmacokinetics. 47: 129-37. PMID 18193919 DOI: 10.2165/00003088-200847020-00006 |
0.313 |
|
| 2008 |
Ramani K, Miclea RD, Purohit VS, Mager DE, Straubinger RM, Balu-Iyer SV. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. Journal of Pharmaceutical Sciences. 97: 1386-98. PMID 17705286 DOI: 10.1002/Jps.21102 |
0.593 |
|
| 2007 |
Abraham AK, Krzyzanski W, Mager DE. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. The Aaps Journal. 9: E181-9. PMID 17614360 DOI: 10.1208/Aapsj0902020 |
0.703 |
|
| 2007 |
Hong Y, Mager DE, Blum RA, Jusko WJ. Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability. Pharmaceutical Research. 24: 1088-97. PMID 17385022 DOI: 10.1007/S11095-006-9232-X |
0.572 |
|
| 2007 |
Mager DE, Abernethy DR. Use of wavelet and fast Fourier transforms in pharmacodynamics. The Journal of Pharmacology and Experimental Therapeutics. 321: 423-30. PMID 17142645 DOI: 10.1124/Jpet.106.113183 |
0.317 |
|
| 2007 |
O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 59: 79-87. PMID 16642371 DOI: 10.1007/S00280-006-0240-7 |
0.306 |
|
| 2006 |
Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Advanced Drug Delivery Reviews. 58: 1326-56. PMID 17092600 DOI: 10.1016/J.Addr.2006.08.002 |
0.401 |
|
| 2006 |
Mager DE. Target-mediated drug disposition and dynamics. Biochemical Pharmacology. 72: 1-10. PMID 16469301 DOI: 10.1016/J.Bcp.2005.12.041 |
0.418 |
|
| 2006 |
Mager DE, Jusko WJ. Mechanistic Pharmacokinetic/Pharmacodynamic Models II Pharmacometrics: the Science of Quantitative Pharmacology. 607-631. DOI: 10.1002/9780470087978.ch23 |
0.42 |
|
| 2005 |
Arnold RD, Mager DE, Slack JE, Straubinger RM. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8856-65. PMID 16361575 DOI: 10.1158/1078-0432.Ccr-05-1365 |
0.613 |
|
| 2005 |
Mager DE, Shirey JD, Cox D, Fitzgerald DJ, Abernethy DR. Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network. Journal of Pharmaceutical Sciences. 94: 2475-86. PMID 16200613 DOI: 10.1002/Jps.20384 |
0.423 |
|
| 2005 |
Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharmaceutical Research. 22: 1589-96. PMID 16180117 DOI: 10.1007/S11095-005-6650-0 |
0.463 |
|
| 2005 |
Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharmaceutical Research. 22: 58-61. PMID 15771230 DOI: 10.1007/S11095-004-9009-Z |
0.515 |
|
| 2004 |
Williams ML, Mager DE, Parenteau H, Gudi G, Tracy TS, Mulheran M, Wainer IW. Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 786-93. PMID 15258102 DOI: 10.1124/Dmd.32.8.786 |
0.321 |
|
| 2004 |
Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, Mager DE. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 632-8. PMID 15155555 DOI: 10.1124/Dmd.32.6.632 |
0.402 |
|
| 2004 |
Segrave AM, Mager DE, Charman SA, Edwards GA, Porter CJ. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. The Journal of Pharmacology and Experimental Therapeutics. 309: 1085-92. PMID 14872093 DOI: 10.1124/Jpet.103.063289 |
0.387 |
|
| 2004 |
Urquidi-Macdonald M, Mager DE, Mascelli MA, Frederick B, Freedman J, Fitzgerald DJ, Kleiman NS, Abernethy DR. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clinical Pharmacology and Therapeutics. 75: 60-9. PMID 14749692 DOI: 10.1016/J.Clpt.2003.09.008 |
0.309 |
|
| 2003 |
Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. Journal of Clinical Pharmacology. 43: 1216-27. PMID 14551176 DOI: 10.1177/0091270003258651 |
0.529 |
|
| 2003 |
Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. The Journal of Pharmacology and Experimental Therapeutics. 307: 969-76. PMID 14534354 DOI: 10.1124/Jpet.103.057299 |
0.413 |
|
| 2003 |
Mager DE, Moledina N, Jusko WJ. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. Journal of Pharmaceutical Sciences. 92: 1521-5. PMID 12820156 DOI: 10.1002/Jps.10402 |
0.501 |
|
| 2003 |
Wyska E, Mager DE, Krzyzanski W. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. Journal of Pharmaceutical Sciences. 92: 1438-54. PMID 12820148 DOI: 10.1002/Jps.10407 |
0.332 |
|
| 2003 |
Levy G, Mager DE, Cheung WK, Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. Journal of Pharmaceutical Sciences. 92: 985-94. PMID 12712418 DOI: 10.1002/Jps.10345 |
0.653 |
|
| 2003 |
Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 510-8. PMID 12695336 DOI: 10.1124/Dmd.31.5.510 |
0.533 |
|
| 2003 |
Mager DE, Pyszczynski NA, Jusko WJ. Integrated QSPR--pharmacodynamic model of genomic effects of several corticosteroids. Journal of Pharmaceutical Sciences. 92: 881-9. PMID 12661073 DOI: 10.1002/Jps.10343 |
0.563 |
|
| 2003 |
Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. The Journal of Pharmacology and Experimental Therapeutics. 306: 262-70. PMID 12660309 DOI: 10.1124/Jpet.103.049502 |
0.549 |
|
| 2002 |
Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharmaceutical Research. 19: 1537-43. PMID 12425473 DOI: 10.1023/A:1020468902694 |
0.568 |
|
| 2002 |
Mager DE, Jusko WJ. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. Journal of Pharmaceutical Sciences. 91: 2441-51. PMID 12379930 DOI: 10.1002/Jps.10231 |
0.526 |
|
| 2001 |
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics. 28: 507-32. PMID 11999290 DOI: 10.1023/A:1014414520282 |
0.581 |
|
| 2001 |
Mager DE, Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. Clinical Pharmacology and Therapeutics. 70: 210-6. PMID 11557908 DOI: 10.1067/Mcp.2001.118244 |
0.479 |
|
| Show low-probability matches. |